Evidence continues to build that serotonergic psychedelics such as psilocybin, DMT, and LSD promote neuroplasticity. Cortical atrophy is involved in the development of a broad swathe of neuropsychiatric conditions ranging from depression to substance use disorder. But it remains unclear how psychedelics may potentially treat mood disorders and other conditions. Despite their therapeutic potential, these…

Ketamine has emerged as a quick-acting antidepressant in recent years. While use of the dissociative anesthetic for depression has exploded, hurdles remain. A single ketamine infusion can cost $400 or more in the U.S. Ketamine can also cause significant transient increases in blood pressure. Furthermore, higher doses of the drug can lead to pronounced states…